Here's Why Conmed (CNMD) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 11, 2025

CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio

CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.

Zacks Investment Research • Dec 8, 2025

Why Is Conmed (CNMD) Up 0.1% Since Last Earnings Report?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today's announcement reflects a positive step in our strategic portfolio review and o.

Business Wire • Dec 5, 2025

Here's Why You Should Add CONMED Stock to Your Portfolio Now

CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.

Zacks Investment Research • Dec 4, 2025

5 Value Stocks With Exciting EV-to-EBITDA Ratios to Scoop Up

PAGP, EIX, SNX, CNMD and PCG stand out with attractive EV-to-EBITDA ratios and strong earnings outlooks.

Zacks Investment Research • Dec 4, 2025

Are Investors Undervaluing CONMED (CNMD) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 2, 2025

Why Conmed (CNMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Nov 27, 2025

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 24, 2025

CNMD vs. MMSI: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Conmed (CNMD) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Nov 24, 2025